for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

United Therapeutics Corporation

UTHR.OQ

Latest Trade

200.08USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

98.37

 - 

216.90

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
200.08
Open
--
Volume
--
3M AVG Volume
6.94
Today's High
--
Today's Low
--
52 Week High
216.90
52 Week Low
98.37
Shares Out (MIL)
44.89
Market Cap (MIL)
8,981.98
Forward P/E
17.64
Dividend (Yield %)
--

Next Event

United Therapeutics Corp Extraordinary Shareholders Meeting

Latest Developments

More

United Therapeutics Corp Posts Qtrly Non-Gaap Earnings, Per Diluted Share $4.09

United Therapeutics Says On June 22, Co, Medtronic Agreed To Discontinue Further Efforts To Develop & Commercialize Implantable System For Remodulin

United Therapeutics Announces FDA Acceptance Of Tyvaso Dpi™ New Drug Application For Priority Review

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About United Therapeutics Corporation

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). The Company markets and sells an oncology product in the United States, Unituxin (dinutuximab) Injection (Unituxin), which is approved for treatment of neuroblastoma. The Company is also engaged in early-stage research and development of a number of organ transplantation-related technologies.

Industry

Biotechnology & Drugs

Contact Info

1040 SPRING ST

SILVER SPRING, MD

20910

United States

+1.301.6089292

http://www.unither.com

Executive Leadership

Martine A. Rothblatt

Chairman of the Board, Chief Executive Officer

Michael Benkowitz

President, Chief Operating Officer

Christopher Patusky

Lead Independent Vice Chairman of the Board

James C. Edgemond

Chief Financial Officer, Treasurer

Paul A. Mahon

Executive Vice President, General Counsel, Corporate Secretary

Key Stats

1.70 mean rating - 10 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

1.6K

2019

1.4K

2020

1.5K

2021(E)

1.7K
EPS (USD)

2018

13.390

2019

-2.390

2020

11.540

2021(E)

11.343
Price To Earnings (TTM)
19.46
Price To Sales (TTM)
5.65
Price To Book (MRQ)
2.47
Price To Cash Flow (TTM)
17.25
Total Debt To Equity (MRQ)
21.98
LT Debt To Equity (MRQ)
21.98
Return on Investment (TTM)
11.08
Return on Equity (TTM)
10.39

Latest News

Latest News

Israel deal should remove any hurdle to F-35 sale, UAE official says

The United Arab Emirates' accord to normalise ties with Israel should remove "any hurdle" for the United States to sell the F-35 stealth fighter jet to the Gulf Arab state, a senior Emirati official said on Thursday.

BRIEF-Liquidia Responds To United Therapeutics Corporation Lawsuit

* LIQUIDIA RESPONDS TO UNITED THERAPEUTICS CORPORATION LAWSUIT

BRIEF-United Therapeutics Files Lawsuit Against Liquidia For Infringement Of Tyvaso Patents

* UNITED THERAPEUTICS CORP - FILES LAWSUIT AGAINST LIQUIDIA FOR INFRINGEMENT OF TYVASO PATENTS

BRIEF-Medicenna Therapeutics Expect To Complete IND Enabling Studies For MDNA109 Superkine Platform By Q1

* MEDICENNA THERAPEUTICS - END OF PHASE 2 MEETING PACKAGE FOR MDNA55 TO BE SUBMITTED IN Q2 2020

BRIEF-United Therapeutics Announces Additional Results From Freedom-Ev Study Showing Hemodynamic And Risk Status Reduction Benefits Of Orenitram Treatment In Patients With Pulmonary Arterial Hypertension

* UNITED THERAPEUTICS ANNOUNCES ADDITIONAL RESULTS FROM FREEDOM-EV STUDY SHOWING THE HEMODYNAMIC AND RISK STATUS REDUCTION BENEFITS OF ORENITRAM TREATMENT IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION

BRIEF-United Therapeutics Says Chairman And CEO Martine Rothblatt's 2019 Total Compensation Was $45.6 Mln Versus $16 Mln In 2018

* UNITED THERAPEUTICS CORP - CHAIRMAN AND CEO MARTINE ROTHBLATT'S 2019 TOTAL COMPENSATION WAS $45.6 MILLION VERSUS $16 MILLION IN 2018 - SEC FILING

BRIEF-Celularity Expands Strategic Collaboration With United Therapeutics

* CELULARITY EXPANDS STRATEGIC COLLABORATION WITH UNITED THERAPEUTICS CORPORATION TO COVID-19 INFECTION AND ACUTE RESPIRATORY DISTRESS SYNDROME

BRIEF-United Therapeutics Corporation Reports Q4 Adjusted Earnings Per Share $1.96

* ORATION REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS

United Therapeutics notches win in fight over blocked generic rival

United Therapeutics Corp can continue to restrict how pharmacies dispense delivery devices for its cardiovascular drug Remodulin, a New Jersey federal judge ruled on Wednesday, dealing a setback to Novartis AG' Sandoz generic drug unit.

Arena Pharma soars on deal with United Therapeutics for hypertension drug

Shares of Arena Pharmaceuticals Inc jumped nearly 30 percent after the drug developer sold rights to develop and sell its hypertension treatment to United Therapeutics Corp, fetching it $800 million in an upfront payment.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up